Newly Diagnosed Head and Neck CRG
Stanford Cancer Center Head and Neck CRG Click here to print this page (PDF) 1 July 2015 Newly Diagnosed Treatment Post Surgery/ High Risk Ameloblastoma RTOG1216 Phase II/III Radiation + Concurrent Cisplatin Vs Docetaxel Vs Decetaxel +Cetuximab in Head & Neck CA ENT0043 A Pilot Study of Dabrafenib for Patients with BRAF-Mutated Ameloblastoma PI: Le RTOG Oropharynx Only P16+ Resection Favorable PI: Colevas Stanford ECOGE3311 Phase II Surgery + Low/Std Dose IMRT in Resectable p16+ Locally Advanced Oropharynx CA PI: Holsinger ECOG Resection Unfavorable NRGHN002 Phase II in p16 Positive, NonSmoking Associated, Locoregionally Advanced Oropharyngeal Cancer Supportive Care Oral Cavity Only Nasopharynx Only ENT0025 Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) NRGHN001 Phase II/III Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus Deoxyribonucleic Acid PI: Colevas Stanford 1st Priority PI: Le NRG 2nd Priority ENT0045 Phase II Neoadjuvant & Adjuvant Tx IRX-2 Regimen in Newly Dx Stage III / IVA SCC of the Oral Cavity PI: Kaplan Pending PI: Le NRG KEY Pending Open for Enrollment Observational Study Optional Path Link Extension Study Trial Posting Enrollment on Hold Please mark up a copy using black ink and fax changes to 725-9204 ENT0042 Phase III Hypochlorite(Modifi ed Dakin's Solution) Tx in Prevention of Radiation Dermatitis in H&N CA PI: Hara Stanford
© Copyright 2024